New Healthcare Insurance Scheme Strengthens Demand for Low-Cost Medicines in Indonesia, Finds Frost & Sullivan
From PR Newswire
March 3 2015
JAKARTA, Indonesia, March 3, 2015 /PRNewswire/ -- Indonesia is rapidly evolving into one of the most attractive healthcare markets for investors. In spite of the initial regulatory hurdles in setting up manufacturing units in Indonesia, companies from every healthcare sector, including hospitals, medical devices, pharmaceuticals and diagnostics, continue to look at the country as a major investment destination.
New analysis from Frost & Sullivan, Indonesia Healthcare Outlook (https://www.frost.com/p80f), finds that Greater Jakartaremains the most promising market due to strong infrastructure support, accessibility, and the presence of major hospitals.Kalimantan and Papua (outer Jakarta) too offer attractive potential. The manufacturing hub, currently in Bandung and Surabaya, is likely to move to newer areas such as Sei Mangke in North Sumatra and Tanjung Lesung in Banten as well as to the existing free-trade zone in the Riau Islands of Batam, Bintan and Karimun.
For complimentary access to more information on this research, please visit:http://corpcom.frost.com/forms/APAC_PR_DJeremiah_P80F-52_30Jan15.
The implementation of the Jaminan Kesehatan Nasional (JKN) insurance scheme has spiked patient volumes significantly, heightening the demand for hospital beds, medical devices, affordable medicines and diagnostic services. A few clinics in Bandung reported up to a 200 percent rise in patient volumes in the first 2 months after the scheme's implementation.
For Detailed story, please click here